



Biotech Daily

Thursday October 8, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: SYNTARA UP 19%; IMPEDIMED DOWN 17%**
- * **CYNATA \$913k RIGHTS OFFER; CANCELS ATM; UNMARKETABLE PARCELS**
- * **CLARITY ENROLS PHASE I/IIa CU-67 SAR-BIS-PSMA COHORT EXPANSION**
- * **QIMR: 'TOPICAL SCABIES THERAPY BEATS IVERMECTIN, IN PIGS'**
- * **IMRICOR: FDA COMPLETES 3rd PRE-MARKET VISION-MR REVIEW**
- * **NOXOPHARM 'CONSTRUCTIVE' FDA PHASE II SOF-SKN FEEDBACK**
- * **NYRADA 4.2m BOARD, MANAGEMENT OPTIONS AGM**
- * **ALGORAE 90m BOARD RIGHTS AGM**
- * **NEXSEN 10m DIRECTOR PROF SHEKHAR KUMTA OPTIONS AGM**
- * **CAMBIUM \$10m SHARE ISSUE, CONDITIONAL BOARD SPILL AGM**

MARKET REPORT

The Australian stock market fell 0.77 percent on Thursday October 8, 2026, with the ASX200 down 66.8 points to 8,660.9 points. Thirteen of the Biotech Daily Top 40 companies were up, 22 fell, three traded unchanged and two were untraded.

Syntara was the best, up 0.4 cents or 19.05 percent to 2.5 cents, with 13.1 million shares traded. Micro-X climbed 7.8 percent; Emvision was up 6.4 percent; Lumos improved five percent; Nova Eye was up 3.85 percent; Imugene, Polynovo and Resmed rose two percent or more; Avita, Prescient and Racura were up more than one percent; with Clarity, Neuren and Starpharma up by less than one percent.

Impedimed led the falls, down 0.1 cents or 16.7 percent to 0.5 cents, with 11.0 million shares traded.

Botanix lost 11.8 percent; Curvebeam was down 9.1 percent; Cyclopharm shed 7.8 percent; EBR and Immutep were down more than six percent; Alcidion and Amplia fell more than four percent; Clinuvel, Mesoblast, Nanosonics and Resonance were down three percent or more; Aroa, Atomo, Dimerix, Optiscan, Orthocell and Saluda shed more than two percent; 4D Medical and Artrya were down one percent or more; with Cochlear, CSL, Imricor, Pro Medicus and Telix down by less than one percent.

CYNATA THERAPEUTICS

Cynata says it will raise \$913,000 in a rights offer, has terminated its at-the-market (ATM) subscription deed and will conduct an unmarketable parcel facility.

Cynata said it would raise \$913,000 at one cent a share in a three-for-eight, fully-underwritten, pro-rata, renounceable entitlement offer.

The company said the issue price was a 9.1 percent discount to both the last closing price and five-day volume weighted average price.

Cynata said the funds raised would be used to pay for adviser, director and consultant fees, as well as working capital.

In July, the company said that, following two negative trial results, all employees, would be made redundant, with a reduced board to evaluate future options (BD: Jul 6, 2026).

Today, Cynata said it was evaluating the development pathways available for its Cymerus stem cell technology and broader options including "seeking opportunities to realize value from the Cymerus technology and obtain rights to new assets".

Separately, the company said it had given notice to terminate its up-to \$7,500,000 at-the-market subscription deed with Acuity Capital, effective from October 14, 2026.

Last year, Cynata said it had an up-to \$7,500,000, five-year at-the-market facility with Acuity Capital, which would expire on July 31, 2030 (BD: Aug 22, 2025).

Today, the company said as security for the facility it had agreed to place 11,500,000 shares for no consideration to Acuity and had used \$1,204,000 of the facility through the set-off of 4,300,000 shares, leaving Acuity with a balance of 7,200,000 shares.

Cynata said subject to consultation with Acuity and shareholder approval it would buy-back and cancel the 7,200,000 shares held as security for no consideration.

The company said it intended to establish an unmarketable parcel sale facility to sell parcels of shares worth less than \$500 without brokerage fees.

Cynata said details of the unmarketable parcel facility would be announced separately; and the rights offer would be managed and underwritten by Caravel Securities.

Cynata said the offer had a record date of October 13, would open on October 16 and close on October 27, 2026.

Cynata was up 0.1 cents or 9.1 percent to 1.2 cents with 11.65 million shares traded.

CLARITY PHARMACEUTICALS

Clarity says it has enrolled 16 treatment patients in the expansion of its phase I/IIa trial of copper-67 Sar-Bis-prostate specific membrane antigen (PSMA) for prostate cancer.

In 2023, Clarity said it had treated the first of 44 patients in its 'Secure' phase I/IIa trial of copper-67 Sar-Bis-PSMA for metastatic prostate cancer (BD: May 24, 2023).

Last year, the company said it treated the first of 24 patients in the expansion cohort of its phase II trial of 8.0GBq (giga-becquerels) of copper-67 Sar-Bis-PSMA for prostate cancer (BD: Apr 15, 2025).

Today, Clarity said the recruitment target for the cohort expansion portion of the trial had been achieved and that recruitment remained ongoing for additional participants to be treated with combination of 8.0GBq copper-67 Sar-Bis-PSMA with enzalutamide.

The company said across the entire copper-67 Sar-Bis-PSMA clinical development program, seven participants had achieved complete response/undetectable disease.

Clarity said most related adverse events were mild or moderate and transient.

The company said additional updates from the cohort expansion phase would "be released in the coming months as data from the most recently enrolled participants continue to mature".

Clarity was up one cent or 0.5 percent to \$1.96 with 3.1 million shares traded.

QUEENSLAND INSTITUTE OF MEDICAL RESEARCH BERGHOFFER

QIMR Berghofer says a study of its topical treatment for scabies shows it outperformed oral ivermectin for clearing the scabies infection in a single dose, in pigs.

QIMR said the treatment “could transform the fight against scabies” which was caused by microscopic mites that burrowed into the skin, causing intense itching, rash and secondary bacterial infections.

The Institute said the treatment combined abametapir, an ingredient in lice treatment, and flavesone, an ingredient found in manuka oil.

QIMR said both compounds killed scabies mites and eggs but abametapir was “particularly effective against eggs while flavesone is especially effective against mites”.

The Institute said that “together, the compounds target multiple stages of the parasite's life cycle through different, non-neurotoxic mechanisms”.

QIMR said the study, titled ‘A single-dose topical therapy cures scabies in a human-relevant porcine model’ was published in Science Translational Medicine, with an abstract available at: <https://bit.ly/4jLH9rX>.

The Institute said the study assessed the combined treatment on a pig model “that closely replicates human scabies infection” and that pigs with established severe scabies received a single topical application, which was washed off after four hours.

QIMR said researchers measured mite survival, egg viability, itch reduction and drug exposure within the skin for 42 days and compared its treatment with the current standard two-dose oral treatment of ivermectin, as well as no treatment.

The Institute said its single treatment eradicated all live mites and eggs and significantly reduced itching, outperforming ivermectin treatment.

IMRICOR MEDICAL SYSTEMS

Imricor says the US Food and Drug Administration has completed a review of its third pre-market approval module for its Vision-MR ablation catheter and other products.

Earlier this year, Imricor said it had filed the third FDA module (BD: Jun 11, 2026).

Today, the company said the module contained the design, execution and results of all non-clinical tests associated with the Vision-magnetic resonance (MR) Ablation Catheter 2.0, RF-5000 System including ablation generator, irrigation pump, and remote unit, and RF-5000 Irrigation Tubing Set.

Imricor said the tests included “product performance, sterile shelf life, packaging integrity, software testing, electrical safety, electro-magnetic compatibility, magnetic resonance safety, and usability”.

The company said the FDA had “identified one deficiency, which requires a response from the company prior to acceptance and closure of the module” related to the software operating system in the RF-5000 system which was no longer under long-term support from its manufacturer.

Imricor said it had “already updated the operating system to a version that is under long-term support, and the company is preparing its response to the FDA”.

Imricor executive chair Steve Wedan said module three “was the largest and most technically detailed part of our [pre-market approval application]”.

“It covers every bench test across the ablation catheter, generator, pump and irrigation tubing set, from product performance and shelf life through to software, cyber-security, electrical safety and MR safety,” Mr Wedan said. “To complete an FDA review of that scope with a single deficiency, and one we have already addressed, is a credit to the rigor our engineering and regulatory teams have applied throughout this program.”

Imricor fell half a cent or 0.3 percent to \$1.445.

NOXOPHARM

Noxopharm says it has “constructive feedback” from the US Food and Drug Administration on its planned phase II trial of SOF-SKN for auto-immune diseases.

Noxopharm said that “at a high level, the FDA was supportive of [its] approach along with the company’s proposal on how this novel technology could fit into the agency’s regulatory framework ... [and the feedback was] particularly supportive of [its] chemical manufacturing strategy, and the agency also considered the proposed phase II trial design as reasonable”.

The company said the FDA “also provided technical guidance to ensure alignment with its expectations around the proposed non-clinical studies”.

Noxopharm said the phase II clinical trial was expected to begin by July 2028, subject to regulatory, clinical and manufacturing requirements.

Noxopharm chief executive officer Dr Olivier Laczka said “engagement with the FDA at this stage is a critical step in our progress along the clinical trials pathway”.

“We appreciate the opportunity to get detailed feedback that will now feed into our phase II preparations,” Dr Laczka said.

Noxopharm fell 0.1 cents or 1.6 percent to 6.1 cents.

NYRADA

Nyrada says its annual general meeting will vote to issue 1,200,000 options to its chair John Moore and 600,000 options, each, to five directors.

Nyrada said investors would vote to issue the options to directors Christopher Cox, Dr Ian Dixon, Marcus Frampton, Dr Ruediger Weseloh and managing-director James Bonnar, exercisable at the 10-day volume weighted average price prior to the first anniversary of the grant date within three years from the vesting date.

The company said the options were in addition to Mr Moore’s \$189,162 annual pay, Mr Cox and Mr Frampton’s \$79,907 yearly fees, each, Dr Dixon’s \$89,558 annual remuneration, Dr Weseloh’s \$72,769 yearly fee and Mr Bonnar’s \$396,660 annual pay.

Nyrada said shareholders would vote to adopt the remuneration report, re-elect Mr Moore, Mr Cox, Dr Dixon, Mr Frampton, Dr Weseloh and Mr Bonnar as directors, approve the 10 percent placement capacity, amend the bylaws for director elections and the equity incentive plan issue cap.

The meeting will be held at Automic Group, Level 5, 126 Phillip Street, Sydney on November 19, 2026 at 8.30am (AEDT).

Nyrada fell one cent or two percent to 49 cents.

ALGORAE PHARMACEUTICALS

Algorae says its annual general meeting will vote to issue 30,000,000 performance rights, each, to directors David Gulland, Troy Valentine and chair David Hainsworth.

Algorae said the rights would be issued for no consideration, vest on market capitalization and revenue-based milestones and were in addition to Mr Gulland’s \$250,000 yearly pay, Mr Valentine’s \$100,000 a year fees and Mr Hainsworth’s \$270,000 annual salary.

The company said investors would vote to adopt the remuneration report, approve the 10 percent placement capacity, elect directors Mr Gulland, Mr Valentine and Mr Hainsworth and ratify the appointment of its auditor.

The meeting will be held at Level 23, Rialto South Tower, 525 Collins Street, Melbourne on November 5, 2026 at 11am (AEDT).

Algorae was unchanged at 0.9 cents with one million shares traded.

NEXSEN

Nexsen says investors will vote to issue executive director Prof Shekhar Kumta 10,000,000 incentive options, exercisable at 40 cents each by September 11, 2029.

Last year, Nexsen said it appointed Prof Kumta as a director and last week said that he had been appointed as an executive director (BD: Dec 3, 2025; Oct 1, 2026).

Today, the company said Prof Kumta's options were in addition to his \$275,000 annual remuneration for his executive, directorial and advisory board roles.

Nexsen said its annual general meeting would vote to adopt the remuneration report, elect Prof Kumta and Grant Pestell as directors, ratify the issue of placement options and approve the additional 10 percent placement capacity.

The meeting will be held at Level 4, 130 Stirling Street, Perth on November 9, 2026 at 11am (AWST).

Nexsen was up half a cent or 3.85 percent to 13.5 cents.

CAMBIUM BIO (FORMERLY REGENEUS)

Cambium says its annual general meeting will vote to issue \$10,000,000 in shares, and a potential remuneration report second strike conditional board spill resolution.

Last year, Cambium said its annual general meeting passed all resolutions but voted a 34.39 percent remuneration report first strike (BD: October 16, 2025).

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 a company with a vote of 25 percent or more against the remuneration report in two successive annual meetings must vote on a board spill.

Today, the company said if resolution nine to issue \$10,000,000 worth of shares was passed, the proposed share issue could "proceed without using any of the company's 15 percent placement capacity under Listing Rule 7.1".

Cambium said if resolution nine was not passed it would "not be able to proceed with the proposed share issue under this approval and would need to rely on its placement capacity under Listing Rules 7.1 and 7.1A or consider alternative funding".

The company said it required "additional capital to fund its pivotal phase III clinical program for Elate Ocular, which comprises a single 475-patient trial".

Cambium said the meeting would vote to adopt the remuneration report, re-elect Dr Edmund Kemp Waller as a director, ratify the prior issue of 2,100,000 shares, 160,000 options and placement shares to directors as well as approve the 10 percent additional placement capacity.

The meeting will be held at online on November 9, 2026 at 11am (AEDT).

Cambium was untraded at 54 cents.